Cuorips Inc.
Stock Price Chart
2026/03/06 UpdatedPrice Trend
2026/03/06 UpdatedPrice & Trading Details
2026/03/06 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/03/01Financial Performance
2026/03/01 UpdatedNo financial data available
Latest IR Information
-
Acquisition of Conditional and Time-limited Manufacturing and Marketing Approval for Human (Allogeneic) iPS Cell-Derived Cardiomyocyte Sheet
Quolips, Inc. announced that it has obtained conditional and time-limited manufacturing and marketing approval from the Ministry of Health, Labour and Welfare for the human (allogeneic) iPS cell-derived cardiomyocyte sheet "Reheart" on March 6, 2026.
Read more -
Status of Manufacturing and Marketing Approval Review for Human (Allogeneic) iPS Cell-Derived Cardiomyocyte Sheets
The Pharmaceuticals and Medical Devices Agency panel has determined that the human (allogeneic) iPS cell-derived cardiomyocyte sheet IPSOC-1 can be approved with conditions and time limitations, and formal approval by the Ministry of Health, Labour and Welfare is expected.
Read more
Latest News (5 items)
Company Information
About
Cuorips Inc. engages in the research, development, manufacture, commercialization, and sale of human iPS cell-derived cardiomyocyte sheets. The company offers cellular and tissue-based, and cell processing products. It also provides contract development and manufacturing, and consulting services. The company was formerly known as Cuore Inc. and changed its name to Cuorips Inc. in June 2017. Cuorips Inc. was incorporated in 2017 and is headquartered in Tokyo, Japan.
